NCT01680965View on ClinicalTrials.gov

Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 14, 2012

Primary Completion Date

August 31, 2020

Study Completion Date

August 30, 2020

Conditions
Chronic Graft Versus Host Disease
Interventions
DRUG

Ofatumumab

"Phase I: test an escalating dose of ofatumumab at cohorts of 300 mg, 700 mg, and 1000 mg given on day 0 and 14 of study.~Phase II: Ofatumumab MTD on day 0 and 14; patients will be followed for total of 24 months (months 1, 3, 6, 12 after therapy, then at 18 and 24 months following therapy)"

Trial Locations (4)

33612

H.Lee Moffitt Cancer Center & Research Institute, Tampa

55455

University of Minnesota, Minneapolis

85054

Mayo Clinic Cancer Center, Phoenix

98109

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT01680965 - Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease | Biotech Hunter | Biotech Hunter